Michael T Kowarik

This inventor holds 37 USPTO granted patents and 16 published patent applications, plus 9 CIPO patents and 20 EPO patents, primarily in Bioconjugate Vaccines. Top assignees: Glaxosmithkline Biologicals Sa, Janssen Pharmaceuticals, Inc., Glycovaxyn Ag. Active years: 2014-2026.

USPTO Granted Patents = 37 (Patent Applications = 16)

% Patents Active = 94.6

CIPO Patents = 9 (Patent Applications = 1)

EPO Patents = 20 (Patent Applications = 32)

Average Co-Inventor Count = 4.9

ph-index = 8

Forward Citations = 133(Granted Patents)

Location History:

Zürich, CH (2014 - 2022)
Zurich, CH (2014 - 2024)
Schlieren, CH (2018 - 2024)

Company Filing History:

30 out of 545

Glaxosmithkline Biologicals Sa

patents

7 out of 161

Janssen Pharmaceuticals, Inc.

Limmatech Biologics Ag

patents

where one patent can have more than one assignee

Years Active: 2014-2026

Loading Chart...

Areas of Expertise:

Bioconjugates

Polysaccharides

Glycosylation

Immunogenic Composition

N-glycosylated Proteins

Host Cell Modification

Enzymatic Conjugation

Vaccine Development

O-antigen Polysaccharides

Pathogenic Immunity

Capsular Bacteria

Protein Composition

37 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12685769 - VACCINE (2026-07-21),

2. 12559731 - MUTATED PGLB OLIGOSACCHARYLTRANSFERASE ENZYMES (2026-02-24),

3. 12442019 - Process for the manipulation of nucleic acids (2025-10-14),

4. 12398380 - Methods of host cell modification (2025-08-26),

5. 12233121 - Methods of producing bioconjugates ofO-antigen polysaccharides, compositions thereof, and methods of use thereof (2025-02-25),

6. 12214029 - Polysaccharide and uses thereof (2025-02-04),

7. 12128096 - Immunogenic composition (2024-10-29),

8. 12076385 - Methods and compositions for immune protection against extra-intestinal pathogenic (2024-09-03),

9. 11959092 - Process for the manipulation of nucleic acids (2024-04-16),

10. 11944675 - Bioconjugates made from recombinant N-glycosylated proteins from procaryotic cells (2024-04-02),

11. 11931405 - Bioconjugates ofO-antigen polysaccharides, methods of production thereof, and methods of use thereof (2024-03-19),

12. 11738076 - Polysaccharide and uses thereof (2023-08-29),

13. 11654190 - Immunogenic composition (2023-05-23),

14. 11491220 - Methods of producing bioconjugates ofo-antigen polysaccharides, compositions thereof, and methods of use thereof (2022-11-08),

15. 11484582 - Methods and compositions for immune protection against extra-intestinal pathogenic (2022-11-01),

Title: The Innovations of Michael T Kowarik: A Visionary in Bioconjugate Research

Introduction: Michael T Kowarik is a prominent inventor located in Zurich, Switzerland, with an impressive portfolio of 27 patents. His innovative work primarily focuses on polysaccharides and their applications in pharmaceutical compositions, particularly in the development of vaccines. Kowarik’s contributions to the field of bioconjugate research have garnered attention, making him a significant figure in the realm of biotechnology.

Latest Patents: One of Kowarik's most notable recent patents is related to a novel polysaccharide designated as O25B. This invention outlines the production of O25B using prokaryotic host cells that contain specialized enzymes, such as glycosyltransferases. The innovative aspect of this patent lies in the ability to produce O25B bioconjugates, which are combinations of O25B linked to carrier proteins. This advancement opens the door for new pharmaceutical compositions that can serve as vaccines against ExPEC infections and may include additional bioconjugates.

Career Highlights: Throughout his career, Michael T Kowarik has made significant strides in the biotechnology industry. He has worked for renowned companies such as GlaxoSmithKline Biologicals and Glycovaxyn AG, where he contributed to various groundbreaking research projects. His extensive experience and dedication to innovation have positioned him as a leader in the development of new therapeutic agents.

Collaborations: Kowarik has closely collaborated with esteemed colleagues, including Michael L Wetter and Stefan Jochen Kemmler. These partnerships have fostered a robust exchange of ideas and knowledge, enhancing the scope of their research efforts and leading to successful innovations in the field.

Conclusion: Michael T Kowarik's journey as an inventor reflects his commitment to advancing biotechnology through innovative solutions in polysaccharides and vaccine development. With a solid foundation of patents and collaborations, Kowarik remains an influential figure in his sector, continually pushing the boundaries of scientific discovery and application.